ABBV vs NAGE

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Niagen Bioscience Inc (NAGE) shows improved fundamental clarity compared to the previous analysis, with confirmed Q1 2026 profitability (EPS beat, 25% YoY net income growth). Analyst sentiment is strong, with an average price target of $16.33, and a remarkably low PEG ratio of 0.15 signals significant expected growth. The market opportunity in NAD+ supplementation and longevity is substantial, bac...